

Elder Pharmaceuticals Ltd.					
UNAUDITED FINANCIAL RESULTS (PROVISINAL) FOR THE QUARTER ENDED 31st MARCH, 2008					
					(Rupees lacs)
Sr. No.	Particulars	Quarter ended 31.03.08 (Unaudited)	Quarter ended 31.03.2007 (Unaudited)	Year ended 31.03.08 (Unaudited)	Previous year ended 31.03.2007 (Audited)
1	Net sales / Income from operations	15640.32	11823.81	54814.33	44925.34
2	Other Income	178.66	48.23	432.82	470.58
	Total Income	15818.98	11872.04	55247.15	45395.92
3	Total Expenditure				
	a) Increase (-) / Decrease (+) in stock in trade	331.62	-690.11	1559.88	1021.79
	b) Consumption of Materials	2538.21	1746.96	8963.24	6984.27
	c) Purchase of traded goods	4701.31	4361.45	16493.46	14046.22
	d) Employees cost	1838.02	1720.53	7104.86	6198.83
	e) Depreciation	363.60	260.72	1264.84	879.42
	f) Other Expenditure	3079.53	2316.09	9644.24	8874.07
4	Total Expenditure	12852.29	9715.64	45030.52	38004.60
5	Interest (Net)	574.38	410.71	1936.22	1281.76
6	Exceptional items	0.00	0.00	0.00	0.00
7	Profit from ordinary activities before tax	2392.31	1745.69	8280.41	6109.56
8	Tax expenses (Refer note number 6 below)	350.00	250.00	1100.00	832.55
9	Net profit from ordinary activities after tax	2042.31	1495.69	7180.41	5277.01
10	Extraordinary items (Net of tax expenses Rs.)	0.00	0.00	0.00	0.00
11	Net profit for the period	2042.31	1495.69	7180.41	5277.01
12	Paid up equity share capital (Face value Rs.10/-)	1879.21	1857.17	1879.21	1860.14
13	Reserves excluding revaluation reserves	-	-	-	30481.68
14	Basic and diluted EPS (Not annualised)	10.87	8.05	38.21	28.87
15	Public shareholding				
	Number of shares	11736017	11657095	11736017	11657095
	Percentage of shareholding	62.45	62.76	62.45	62.76
Notes:					
1) The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 30th April, 2008.					
2) The statutory Auditors have carried out a limited review of the financial results for the quarter ended 31st March, 2008					
3) During the quarter 70586 equity shares of Rs.10/- each were allotted to employees under Elder ESOP 2004 scheme.					
4) The Company operate in Pharmaceutical segment only. Hence, pursuant to accounting standard AS-17 on segment reporting, segmental information is not required to be given.					
5) Investor complaints pending at the beginning of the quarter - Nil. Received during the quarter -1. Pending at the end of the quarter - Nil					
6) Provision for Tax includes deferred tax and fringe benefit tax.					
Place: Mumbai					
Date: 30th April, 2008					